Novavax (NVAX) could see huge gains soon
Novavax, Inc (NVAX) currently trades at $15.24 and has grown by 10% today. Novavax’s strength stems from the growing excitement over its COVID-19 vaccine program, as well as the strong showing of its flu vaccine, NanoFlu, in a late-stage trial for elderly patients. NanoFlu, in short, produced a favorable efficacy profile compared with Sanofi’s Fluzone Quadrivalent in this treatment-resistant population, while sporting a fairly similar safety record compared with this Food and Drug Administration (FDA)-approved flu vaccine.
Based on this information, investorsQ rates this stock 6 out of 10. We give it this rating based on current information. Novavax’s stock would almost certainly triple in value from here if NanoFlu is approved. A market cap of $2.16 billion, after all, works out to only 3.9 times Wall Street’s low-end peak sales estimate for NanoFlu. The high forecast for Novavax, Inc is $24.00 and the low is $19.00. Notably, the company’s market cap is $793.03 million with a 52 week high of $17.71 and a 52 week low of $3.54.